Entering text into the input field will update the search result below

Innoviva to acquire La Jolla Pharma for $149M including debt

Jul. 11, 2022 7:46 AM ETInnoviva, Inc. (INVA)INVABy: Dulan Lokuwithana, SA News Editor8 Comments

word m and a made with wood building blocks, stock image

Maks_Lab/iStock via Getty Images

  • Innoviva, Inc. (INVA), a diversified holding company, has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $6.23 per share in cash, implying an enterprise value of ~$149M, the companies announced on Monday.

Recommended For You

Comments (8)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

good riddance. bought at $30
Long term loser, but at least now I exit at greater than zero.
joezapp profile picture
Just another in a long list of biotechs that were long-term money pits.
Chris Lau profile picture
@joezapp is that a bullish or bearish comment?
joezapp profile picture
@Chris Lau Money pit means throw money away. Been following this one since the 1990s.
Works for me. So long LJPC.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.